Literature DB >> 7285003

Improved methotrexate therapy of murine tumors obtained by probenecid-mediated pharmacological modulation at the level of membrane transport.

F M Sirotnak, D M Moccio, C H Hancock, C W Young.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7285003

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  3 in total

1.  Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid.

Authors:  M B Lilly; G A Omura
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

2.  Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.

Authors:  Chad R Schultz; Matthew A Swanson; Thomas C Dowling; André S Bachmann
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-15       Impact factor: 3.333

3.  Effects of 5,8-dideazaisopteroylglutamate (IAHQ) on L1210 leukemia in mice when given alone and in combination with methotrexate, probenecid, or verapamil.

Authors:  J B Hynes; A B Smith; G R Gale
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.